Provided by Tiger Trade Technology Pte. Ltd.

MannKind

4.15
-0.1100-2.58%
Post-market: 4.12-0.0300-0.72%19:30 EDT
Volume:3.20M
Turnover:13.59M
Market Cap:1.33B
PE:-29.64
High:4.36
Open:4.28
Low:4.11
Close:4.26
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:0.82
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-19.86
PE(LYR):207.50

Loading ...

MannKind Posts Transcript of Nintedanib DPI Phase 1b Results Call

Reuters
·
Aug 01

MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says

MT Newswires Live
·
Jul 30

MannKind is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Teva Pharmaceutical (TEVA) and MannKind (MNKD)

TIPRANKS
·
Jul 30

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

TIPRANKS
·
Jul 30

MannKind price target raised to $14 from $11 at Wells Fargo

TIPRANKS
·
Jul 30

Earning Preview: MannKind Q2 revenue expected to rise about 39%, institutional views tilt positive

Earnings Agent
·
Jul 30

MannKind Says Phase 1b Study Shows Idiopathic Pulmonary Fibrosis Treatment Generally Safe, Well-Tolerated

MT Newswires Live
·
Jul 29

MannKind Corp - Nintedanib DPI Generally Safe and Well Tolerated in Phase 1B Ipf Study

THOMSON REUTERS
·
Jul 29

MannKind Reports Positive Phase 1B Inflo-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in Ipf

THOMSON REUTERS
·
Jul 29

MannKind Corp - no Serious Adverse Events or Discontinuations Reported in Phase 1B Inflo-1 Study

THOMSON REUTERS
·
Jul 29

MannKind Reports Positive Phase 1b Inflo-1 Results for Inhaled Nintedanib in IPF

Reuters
·
Jul 29

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

GlobeNewswire
·
Jul 29

Health Rounds: MannKind Injection Helps Heart Failure Patients Avoid ER Infusions

Reuters
·
Jul 29

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Bruker (BRKR) and BrightSpring Health Services, Inc. (BTSG)

TIPRANKS
·
Jul 27

The Bull Case For MannKind (MNKD) Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why

Simply Wall St.
·
Jul 25

MannKind Raises $50 Million in Private Placement

TIPRANKS
·
Jul 25

Mannkind Wins FDA Approval for Furoscix Readyflow Autoinjector to Treat Edema in Adults with Heart Failure or CKD

Reuters
·
Jul 25

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MT Newswires Live
·
Jul 24